Neurology Emergencies Grand Rounds Series

Presented on Webex:
To register for this training session, go to:
https://ttuhscep.webex.com/webappng/sites/ttuhscep/meeting/info/f92234c0a9764a14bc756ab764d89c
d3?siteurl=ttuhscep&MTID=m934b1d90906eac32bc13855d4f4f1838

Meeting number (access code): 2598 282 2365
Meeting password: Neuro1

Friday, Nov. 12, 2021
7:45 – 8:45 a.m.

Next-Generation Sequencing To Identify Molecular Signatures in CNS Tumors

Presented by:
Jude Abadie, Ph.D., DABCC, FAACC, DABMGG, FACMG
Associate Professor
Director, Clinical Pathology
Paul L. Foster School of Medicine
Texas Tech University Health Sciences Center El Paso
El Paso, Texas

Objectives: Upon completion of this session, the participant should be able to:

• Identify a molecular genetic mechanism in the development of a CNS tumor.
• Explain how molecular technology can guide diagnosis in CNS tumors.
• Evaluate next-generation sequencing results in the context of CNS tumor prognosis.
• Interpret results of a cancer gene panel to formulate the molecular pathology report.

Accreditation: The Texas Tech University Health Sciences Center El Paso Paul L. Foster School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The Texas Tech University Health Sciences Center El Paso Paul L. Foster School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

To claim CME credit, participants must log on using their full name and remain logged on for a minimum of 75%, if not the entirety of the CME activity. Attendance logs with entry and exit time stamps will be used to validate attendance requirements.

It is the policy and practice of the Texas Tech University Health Sciences Center El Paso Paul L. Foster School of Medicine Office of Continuing Medical Education (CME) to resolve all potential conflicts of interest prior to the activity.

All speakers and the planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing health care products used by or on patients with the exception of:
Salvador Cruz-Flores, M.D., M.P.H., activity director, has disclosed that he was on the Novo Nordisk adjudication committee for RCT. This relevant financial relationship has ended. Dr. Cruz-Flores is on the adjudication committee for RCT for Galapagos.

- CME reserves the right to cancel this activity in the event of unforeseen or extenuating circumstances.
- Persons with disabilities who need auxiliary aids or services may call the Office of CME at 915-215-4880 to arrange accommodation.